

Encephalitis Antibody Panel (CSF)

Reporting Title: Encephalitis Antibody Panel (CSF)

Performing Location: Focus Diagnostics,

#### **Specimen Requirements:**

Submit 5 mL of spinal fluid (CSF). Refrigerate specimen after collecting and ship at refrigerate temperature in a sterile, plastic screw-cap vial.

Specimen Type	Temperature	Time
CSF	Refrigerated (preferred)	7 days
	Frozen	30 days

#### **Result Codes:**

Result ID	Reporting Name	Туре	Unit	LOINC®
Z2856	LCM IgG	Alphanumeric Alphanumeric Alphanumeric		In Process
Z2857	LCM IgM			In Process
Z2858	Interpretation			In Process
Z2859	Measles (Rubeola) IgG, IFA Alphanumeric			In Process
Z2860	Measles (Rubeola) IgM, IFA	Alphanumeric		In Process
Z2861	Interpretation	Alphanumeric		In Process
Z2862	Mumps Ab IgG, IFA	Alphanumeric		In Process
Z2863	Mumps Ab IgM, IFA	Alphanumeric		In Process
Z2864	Interpretation Alphanumeric			In Process
Z2865	VZV Total Ab (ACIF)	Alphanumeric		In Process
Z2866	VZV IgM (IFA)	Alphanumeric		In Process
Z2867	Interpretation	Alphanumeric		In Process
Z3239	West Nile Ab IgG, CSF	Alphanumeric		In Process
Z3240	West Nile Ab IgM, CSF	Alphanumeric		In Process
Z2871	HSV 1 IgG Index	Alphanumeric		In Process
Z2872	HSV 2 IgG Index	Alphanumeric		In Process
Z2873	HSV 1 IgM Screen	Alphanumeric		In Process
Z2874	HSV 2 IgM Screen	Alphanumeric		In Process



**Encephalitis Antibody Panel (CSF)** 

#### **Components:**

Test ID	Reporting Name	CPT Units	CPT Code	Always Performed	Orderable Separately
FLCAC	FLCAC LCM Virus Ab, IFA CSF			Yes	No
FMGMC	Measles (Rubeola) G/M Ab, IFA CSF			Yes	No
FMABP Mumps Antibody Panel, IFA (CSF)  FVZTC Varicella-Zoster, Total/IgM Ab, CSF  FWNAB West Nile Virus Ab (IgG, IgM), CSF  FHSGC HSV 1/2 (IgG) Type-Specific Ab, CSF				Yes	No
				Yes	No
				Yes	No
				Yes	No
FHSMC	Herpes Simplex Virus 1/2 IgM Ab,CSF			Yes	No

#### **CPT Code Information:**

86727 x 2 - Lymphocytic Choriomeningitis

86765 x 2 - Rubeola

86735 x 2 - Mumps

86787 x 2 - Varicella-zoster

86788 - West Nile Virus, IgM

86789 - West Nile Virus, IgG

86695 - Herpes simplex, type 1

86696 - Herpes simplex, type 2

86695 - Herpes simplex, type 1 IgM Titer (if appropriate)

86696 - Herpes simplex, type 2 IgM Titer (if appropriate)

#### **Reflex Tests:**

Test ID	Reporting Name	CPT Units	CPT Code	Always Performed	Orderable Separately
FMTR1	HSV 1 IgM Titer		Profile	No	No
FMTR2	HSV 2 IgM Titer	1	86696	No	No

Encephalitis Antibody Panel (CSF)

#### **Result Codes for Reflex Tests:**

Test ID	Result ID	Reporting Name	Туре	Unit	LOINC®
FMTR1	Z2957	HSV 1 IgM Titer	Alphanumeric		In Process
FMTR2	Z2958	HSV 2 IgM Titer	Alphanumeric		In Process

#### **Reference Values:**

Encephalitis Antibody Panel (CSF)

Lymphocytic Choriomeningitis (LCM) Virus Ab, IFA (CSF)

Reference Range: IgG <1:1 IgM <1:1

Diagnosis of infections of the central nervous system can be accomplished by demonstrating the presence of intrathecally-produced specific antibody. However, interpreting results is complicated by low antibody levels found in CSF, passive transfer of antibody from blood and contamination via bloody taps.

This assay was developed and its performance characteristics determined by Focus Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

Measles (Rubeola) IgG and IgM Antibody Panel (CSF)

Reference Range: IgG <1:64 IgM <1:1

Diagnosis of infections of the central nervous system can be accomplished by demonstrating the presence of intrathecally-produced specific antibody. Interpreting results may be complicated by low antibody levels found in CSF, passive transfer of antibody from blood and contamination via bloody taps. The interpretation of CSF results must consider CSF-serum antibody ratios to the infectious agent.

This assay was developed and its performance characteristics determined by Focus Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

Mumps Antibody Panel, IFA (CSF)

Reference Range: IgG <1:8 IgM <1:1

Diagnosis of infections of the central nervous system can be accomplished by demonstrating the presence of intrathecally-produced specific antibody. Interpretation of results may be complicated by low antibody levels found in CSF, passive transfer of antibody from blood and contamination via bloody taps. The interpretation of CSF results must consider CSF-serum antibody ratios to the infectious agent.



Encephalitis Antibody Panel (CSF)

This assay was developed and its performance characteristics determined by Focus Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

Varicella-Zoster Virus (VZV) Antibody (Total, IgM), ACIF/IFA, CSF

Reference Ranges: VZV Total AB <1:2

VZV IgM <1:1

Diagnosis of infections of the central nervous system can be accomplished by demonstrating the presence of intrathecally-produced specific antibody. Interpreting results may be complicated by low antibody levels found in CSF, passive transfer of antibody from blood and contamination via bloody taps. The interpretation of CSF results must consider CSF-serum antibody ratios to the infectious agent.

This assay was developed and its performance characteristics determined by Focus Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

West Nile Virus Antibodies (IgG, IgM), CSF

Reference Range: IgG <1.30

IgM < 0.90

Interpretive Criteria:

IgG: <1.30 Antibody not detected

1.30 - 1.49 Equivocal

>=1.50 Antibody detected

IgM: <0.90 Antibody not detected

0.90 - 1.10 Equivocal

>1.10 Antibody detected

West Nile Virus (WNV) IgM is usually detectable in CSF from WNV-infected patients with encephalitis or meningitis at the time of clinical presentation. Because IgM antibody does not readily cross the blood-brain barrier, IgM antibody in CSF strongly suggests acute central nervous system infection. WNV antibody results from CSF should be interpreted with caution. Possible complicating factors include low levels of antibody found in CSF, passive transfer of antibodies from blood and contamination via bloody spinal taps. Antibodies induced by other flavivirus infections (e.g. Dengue virus, St. Louis encephalitis virus) may show cross-reactivity with WNV.

Herpes Simplex Virus 1/2 (IgG) Type Specific Antibodies, CSF

Reference Range: < or = 1.00

Interpretive Criteria:

Detection of HSV type-specific IgG in CSF may indicate central nervous system (CNS) infection by that HSV type. However, interpretation of results may be complicated by a number of factors, including low antibody levels found in CSF, passive transfer of antibody across the blood-brain barrier, and serum contamination of CSF during CSF collection. PCR detection of type-specific HSV DNA in CSF is the preferred method for identifying HSV CNS infections.

Herpes Simplex Virus 1/2 Antibody (IgM), IFA with Reflex to Titer, CSF

Reference Range: Negative



Encephalitis Antibody Panel (CSF)

The IFA procedure for measuring IgM antibodies to HSV 1 and HSV 2 detects both type-common and type-specific HSV antibodies. Thus, IgM reactivity to both HSV 1 and HSV 2 may represent crossreactive HSV antibodies rather than exposure to both HSV 1 and HSV 2.

Diagnosis of central nervous system infections can be accomplished by demonstrating the presence of intrathecally-produced specific antibody. Interpreting results may be complicated by low antibody levels found in CSF, passive transfer of antibody from blood and contamination via bloody taps. The interpretation of CSF results must consider CSF-serum antibody ratios to the infectious agent.

This test was developed and its characteristics have been determined by Focus Diagnostics. Performance characteristics refer to the analytical performance of the test.

Test Performed by: Focus Diagnostics, Inc.

5785 Corporate Avenue Cypress, CA 90630-4750